Connection
Neil Aggarwal to Antibodies, Monoclonal
This is a "connection" page, showing publications Neil Aggarwal has written about Antibodies, Monoclonal.
|
|
Connection Strength |
|
 |
|
 |
|
0.199 |
|
|
|
-
Aggarwal NR, Beaty LE, Bennett TD, Carlson NE, Davis CB, Kwan BM, Mayer DA, Ong TC, Russell S, Steele J, Wogu AF, Wynia MK, Zane RD, Ginde AA. Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients. J Infect Dis. 2022 12 13; 226(12):2129-2136.
Score: 0.133
-
Douin DJ, Wogu AF, Beaty LE, Carlson NE, Bennett TD, Aggarwal NR, Mayer DA, Ong TC, Russell S, Steele J, Peers JL, Molina KC, Wynia MK, Ginde AA. Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients. BMC Infect Dis. 2022 Nov 07; 22(1):818.
Score: 0.033
-
Douin DJ, Siegel L, Grandits G, Phillips A, Aggarwal NR, Baker J, Brown SM, Chang CC, Goodman AL, Grund B, Higgs ES, Hough CL, Murray DD, Paredes R, Parmar M, Pett S, Polizzotto MN, Sandkovsky U, Self WH, Young BE, Babiker AG, Davey VJ, Kan V, Gelijns AC, Matthews G, Thompson BT, Lane HC, Neaton JD, Lundgren JD, Ginde AA. Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery. Am J Respir Crit Care Med. 2022 09 15; 206(6):730-739.
Score: 0.033
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|